Literature DB >> 32623637

Effects of glucagon-like peptide-1 receptor agonists on fluid intake in healthy volunteers.

Bettina Winzeler1,2, Ismael da Conceição3,4, Julie Refardt3,4, Clara O Sailer3,4, Gilles Dutilh4, Mirjam Christ-Crain3,4.   

Abstract

PURPOSE: Glucagon-like peptide-1 (GLP-1) receptor agonists (RA) reduce appetite and energy intake. Recent findings from animal studies suggest a role of GLP-1 in drinking and water homeostasis. We aimed to elucidate whether GLP-1 RA reduce fluid intake in healthy volunteers.
METHODS: Double-blind, randomized, placebo-controlled, crossover study. 20 healthy volunteers received dulaglutide 1.5 mg and placebo (0,9% sodium chloride) subcutaneously once weekly for 3 weeks. At the end of each treatment period, participants attended an 8-h evaluation visit, during which they were requested to eat two standardized meals and to drink water ad libitum. The primary outcome was the total fluid intake (ml) during the evaluation visit.
RESULTS: Mean [SD] age of participants (60% female) was 27 [9.2] years. All but four participants drank less on dulaglutide versus placebo treatment despite identical food intake. The median [IQR] difference of fluid intake on dulaglutide compared to placebo treatment was -100 ml [-400-0]. Median [IQR] total fluid intake was 1300 ml [888-1600] versus 1600 ml [1000-1720], on dulaglutide and placebo treatment, p = 0.06. Median [IQR] 24-h urine output was reduced in dulaglutide versus placebo-treated participants: 1250 ml [975-2080] versus 1680 ml [1400-2040], p = 0.04. Median serum sodium levels were 140 mmol/L on both visits and no difference in thirst perception was noted.
CONCLUSIONS: GLP-1 RA such as dulaglutide seem to modulate fluid balance in humans. This leads us to speculate that GLP-1 RA may be an interesting therapeutic options for patients with excessive drinking behavior e.g., primary polydipsia.

Entities:  

Keywords:  Dulaglutide; GLP-1; Hypophysis; Pituitary; Thirst

Mesh:

Substances:

Year:  2020        PMID: 32623637     DOI: 10.1007/s12020-020-02394-2

Source DB:  PubMed          Journal:  Endocrine        ISSN: 1355-008X            Impact factor:   3.633


  20 in total

1.  Glucagon-like peptide-1 is involved in sodium and water homeostasis in humans.

Authors:  Jean-Pierre Gutzwiller; Petr Hruz; Andreas R Huber; Christian Hamel; Carlos Zehnder; Juergen Drewe; Heike Gutmann; Zeno Stanga; Daniel Vogel; Christoph Beglinger
Journal:  Digestion       Date:  2006       Impact factor: 3.216

Review 2.  Brain-gut peptides and the control of food intake.

Authors:  G P Smith; J Gibbs
Journal:  Adv Biochem Psychopharmacol       Date:  1981

3.  Vasopressin and the Regulation of Thirst.

Authors:  Daniel G Bichet
Journal:  Ann Nutr Metab       Date:  2018-06-20       Impact factor: 3.374

4.  Glucagon-like peptide-1 promotes satiety and reduces food intake in patients with diabetes mellitus type 2.

Authors:  J P Gutzwiller; J Drewe; B Göke; H Schmidt; B Rohrer; J Lareida; C Beglinger
Journal:  Am J Physiol       Date:  1999-05

5.  Glucagon-like peptide-1 receptor agonists suppress water intake independent of effects on food intake.

Authors:  Naomi J McKay; Scott E Kanoski; Matthew R Hayes; Derek Daniels
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2011-10-05       Impact factor: 3.619

Review 6.  Glucagon-like peptide 1 in health and disease.

Authors:  Andreas Andersen; Asger Lund; Filip K Knop; Tina Vilsbøll
Journal:  Nat Rev Endocrinol       Date:  2018-07       Impact factor: 43.330

7.  Antidiabetogenic effect of glucagon-like peptide-1 (7-36)amide in normal subjects and patients with diabetes mellitus.

Authors:  M Gutniak; C Orskov; J J Holst; B Ahrén; S Efendic
Journal:  N Engl J Med       Date:  1992-05-14       Impact factor: 91.245

8.  A role for glucagon-like peptide-1 in the central regulation of feeding.

Authors:  M D Turton; D O'Shea; I Gunn; S A Beak; C M Edwards; K Meeran; S J Choi; G M Taylor; M M Heath; P D Lambert; J P Wilding; D M Smith; M A Ghatei; J Herbert; S R Bloom
Journal:  Nature       Date:  1996-01-04       Impact factor: 49.962

9.  Satiety: the roles of peptides from the stomach and the intestine.

Authors:  J Gibbs; G P Smith
Journal:  Fed Proc       Date:  1986-04

10.  Glucagon-like peptide-1 (GLP-1): effect on kidney hemodynamics and renin-angiotensin-aldosterone system in healthy men.

Authors:  Jeppe Skov; Anders Dejgaard; Jørgen Frøkiær; Jens Juul Holst; Thomas Jonassen; Søren Rittig; Jens Sandahl Christiansen
Journal:  J Clin Endocrinol Metab       Date:  2013-03-05       Impact factor: 5.958

View more
  2 in total

1.  A randomized controlled trial of the GLP-1 receptor agonist dulaglutide in primary polydipsia.

Authors:  Bettina Winzeler; Clara O Sailer; David Coynel; Davide Zanchi; Deborah R Vogt; Sandrine A Urwyler; Julie Refardt; Mirjam Christ-Crain
Journal:  J Clin Invest       Date:  2021-10-15       Impact factor: 14.808

Review 2.  Safety of Semaglutide.

Authors:  Mark M Smits; Daniël H Van Raalte
Journal:  Front Endocrinol (Lausanne)       Date:  2021-07-07       Impact factor: 5.555

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.